

Institutional Biosafety Committee

6/6/2025, 12:00PM – 12:50PM

Teleconference

Minutes

Voting Members Present: Brian Taylor, Ami A. Patel, Marianne Cloeren, Ron McNeil, J. Kristie Johnson, John O'Neill, Irina Luzina, Matthew Frieman, Robert Ernst, Matthew Fischer

Voting Members Absent: Karen Scanlon, Alan Schmaljohn, Melissa Morland, Elizabeth Bramhall, Anthony Kim, Janna Barcelo, Theresa Marth, Joseph Gillespie, Sherry Bohn, Ciaran Skerry, Jessie Duggan, Alfredo Garzino-Demo

Other Person(s) Present: Chinwendu Carter, Megan Laffoon

Staff Present: Matthew Fischer, John O'Neill, Holda Ramos

1 Vote on Last Meeting's Minutes

Institutional Biosafety Committee meeting on 5/2/2025

Votes to approve minutes: 9, Disapprove: 0, Abstain: 0

2 New Business

This meeting of the IBC is open to the public pursuant to the NIH Guidelines, Section IV-B-2-a-(6).

- The 2024 DURC/PEPP policy was rescinded by Executive Order on May 5th, just before it was scheduled to go into effect.
 - A new policy is expected within 120 days. In the meantime, federally funded research that meets the definition of "Dangerous Gain of Function" should be paused.
 - Thanks to all who worked diligently over the past 12 months to ensure UMB would have been in compliance on May 6th, including IBC members.
 - As the 2024 DURC/PEPP policy would have superseded the 2014 DURC policy, the 2014 procedures for IRE identification of DURC are still in effect.
 - The meeting of the IRE scheduled for today has been cancelled.
- The NIH Office of Science Policy has mandated changes related to IBC transparency.
 - For all IBC meetings after June 1st, minutes must be posted on an institutional website after they are approved and redacted as needed. This will start with this meeting.
 - IBC rosters are now available to the public on the NIH IBC registration website.
 - UMB Enterprise Risk Management was engaged to discuss risks to individuals related to the two points listed above.
- Our next meeting is scheduled for Friday, July 11th. This is the 2nd Friday of the month due to proximity to the holiday weekend.

- Member issues
 - None discussed.

3 Select Agent Program Oversight

- The incident response plan and laboratory SOPs are on the agenda for annual committee review. Several links and included documents (like the CDC/APHIS Form 3) were updated, but no significant changes were made.
- We have not received the inspection report as of yet for the Select Agent verification inspection that occurred in April.

4 Reportable Incidents

- No reportable events occurred this month.

5 New IBC Submission

Short Title: IBC Submission: 2511GCCC: IMA203 vs. Investigator's Choice of Treatment in Adults w/ Melanoma

Investigator: Petr Hausner

ID: IBC-00008206

Analyst: John O'Neill

IRB Protocol: HP-00113538

VA-Related: No

Discussion: This protocol involves the use of autologous T-cells which will be transduced with a lentiviral vector for the treatment of melanoma. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-C-1 and is approved using BSL-2 facilities and practices.

Motion: Approve

Vote: For: 9, Against: 0, Abstained: 0, Recused: 0

6 Modification Discussions

Short Title: Development and evaluation of novel nanotherapies for glioblastoma in clinically relevant animal models

Investigator: Graeme Woodworth

ID: IBC-00002350

Analyst: Holda Ramos

VA-Related: No

Discussion: This protocol was previously approved for use of recombinant tumor cell lines in animals. This work is classified by the NIH Guidelines for Recombinant or Synthetic Nucleic Acid Molecules as III-D-4-b using BSL-2 and ABSL-2 facilities and practices. It has been modified to change committee-approved precautions to administer tumor cell lines to animals outside of a biosafety cabinet. PPE described includes eye protection and masks as outlined in the OSHA bloodborne pathogen standard. The following

modification is required to secure approval: Remove the sentence that states injection is not an aerosol producing procedure.

Motion: RMSA

Vote: For: 9, Against: 0, Abstained: 0, Recused: 0

Short Title: Target Validation and Screening (CBT) and Therapeutic Working Group (TWG)

Investigator: David Weber

ID: IBC-00004265

Analyst: John O'Neill

VA-Related: No

Discussion: This modification involves the use of previously transduced murine cells in animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-4-a using ABSL-1 facilities and practices. The following modification is required to secure approval: Elaborate further for the experimental design.

Motion: RMSA

Vote: For: 9, Against: 0, Abstained: 0, Recused: 0

Short Title: Anti-Cancer Therapies

Investigator: Joseph P Stains

ID: IBC-00006568

Analyst: Holda Ramos

VA-Related: No

Discussion: This modification involves the use of previously transfected murine carcinoma cells in animals. This work is classified by the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules as III-D-4-a using BSL-1/ABSL-1 facilities and practices. The following modification is required to secure approval: Update answers for risk group, replication competence, and antibiotic resistance for cells.

Motion: RMSA

Vote: For: 9, Against: 0, Abstained: 0, Recused: 0

Short Title: Molecular Imaging Mouse

Investigator: Vikas Kundra

ID: IBC-00006585

Analyst: John O'Neill

VA-Related: No

Discussion: This modification involves the use of adenovirus, retrovirus, and lentiviral vectors used in *E. coli* and mammalian cells, which will be used in animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-1-a using BSL-2/ABSL-2 facilities and practices with sharps precautions. This modification also involves the use of AAV used in *E. coli* and mammalian cells, which will be used in animals. This work is classified by the NIH Guidelines for Research with Recombinant or

Synthetic Nucleic Acids as III-D-4-a using BSL-1/ABSL-1 facilities and practices. The following modification is required to secure approval: remove any recombinant DNA entries which were made redundant by the latest modification.

Motion: RMSA

Vote: For: 9, Against: 0, Abstained: 0, Recused: 0

Short Title: Abnormal DNA repair in cancer

Investigator: Feyruz Rassool

ID: IBC-00000289

Analyst: John O'Neill

VA-Related: No

Discussion: This modification involves the use of previously transduced human and murine cells in animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-4-b and is approved using BSL-2/ABSL-2 facilities and practices.

Motion: Approve the Modification

Vote: For: 9, Against: 0, Abstained: 0, Recused: 0

Short Title: Computational Approach to In Vivo Genome Editing in the Brain

Investigator: Miroslaw Janowski

ID: IBC-00005346

Analyst: John O'Neill

VA-Related: Yes

Discussion: This modification involves the use of AAV in mammalian cells and animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-1-a and is approved using BSL-2/ABSL-1 facilities and practices.

Motion: Approve the Modification

Vote: For: 9, Against: 0, Abstained: 0, Recused: 0

Short Title: Vascular signaling plasticity

Investigator: Thomas Longden

ID: IBC-00006386

Analyst: John O'Neill

VA-Related: No

Discussion: This modification involves the use of AAV in animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-4-a and is approved using ABSL-1 facilities and practices.

Motion: Approve the Modification

Vote: For: 9, Against: 0, Abstained: 0, Recused: 0

Short Title: Molecular and Functional Studies of Depression and Addiction on Brain

Investigator: Mary Kay Lobo

ID: IBC-00001687
Analyst: Holda Ramos
VA-Related: No
Discussion: This modification involves the addition of several AAV constructs which will be used in animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-4-a and is approved using ABSL-1 facilities and practices.
Motion: Approve the Modification
Vote: For: 9, Against: 0, Abstained: 0, Recused: 0

Short Title: Role of SUR1-TRPM4 in neuronal hyperexcitability underlying seizures
Investigator: Vladimir V. Gerzanich
ID: IBC-00007723
Analyst: John O'Neill
VA-Related: No
Discussion: This modification involves the use of AAV in rodent cells and animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-4-a and is approved using BSL-1/ABSL-1 facilities and practices.
Motion: Approve the Modification
Vote: For: 10, Against: 0, Abstained: 0, Recused: 0

Short Title: Translational Laboratory Shared Service (TLSS)
Investigator: Rena Lapidus
ID: IBC-00001298
Analyst: John O'Neill
VA-Related: No
Discussion: This modification involves the use of previously transduced human cells in animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-1-a and is approved using BSL-2/ABSL-2 facilities and practices.
Motion: Approve the Modification
Vote: For: 10, Against: 0, Abstained: 0, Recused: 0

Short Title: Maintenance of transgenic and wild type zebrafish for molecular endocrinology and developmental biology studies.
Investigator: Yonathan Zohar
ID: IBC-00002423
Analyst: John O'Neill
VA-Related: No
Discussion: This modification involves the use of plasmids for the creation of transgenic animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-4-a and is approved using ABSL-1 facilities and practices. This modification also involves the use of Crispr/Cas9 technology without a vector to create transgenic animals. This work is classified by the NIH Guidelines for Research with

Recombinant or Synthetic Nucleic Acids as III-D-4-a and is approved using ABSL-1 facilities and practices.
Motion: Approve the Modification
Vote: For: 10, Against: 0, Abstained: 0, Recused: 0

Short Title: Dissecting Neural Circuits of Learning and Emotion
Investigator: Barbara Juarez
ID: IBC-00007058
Analyst: Holda Ramos
VA-Related: No
Discussion: This modification involves the addition of new AAV constructs and plasmids in animals using CRISPR/Cas9 technology. This work is classified by the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules as III-D-4-a and is approved using BSL-1 and ABSL-1 facilities and practices.
Motion: Approve the Modification
Vote: For: 10, Against: 0, Abstained: 0, Recused: 0

Short Title: Proteolytic Pathways in Venous Thrombus Resolution
Investigator: Toni Antalis
ID: IBC-00000479
Analyst: John O'Neill
VA-Related: Yes
Discussion: This modification involves the use of adenoviral vectors in murine and human cells which will be used in animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-1-a and is approved using BSL-2/ABSL-2 facilities and practices.
Motion: Approve the Modification
Vote: For: 10, Against: 0, Abstained: 0, Recused: 0

Short Title: Role of Drug Transporters in Xenobiotic Disposition and Transporter Physiology
Investigator: Yan Shu
ID: IBC-00000213
Analyst: Holda Ramos
VA-Related: No
Discussion: This modification involves the addition of a new gene of interest and a new lentiviral construct. This work is classified by the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules as III-D-1-a and is approved using BSL-2 and ABSL-2 facility and practices with sharps precautions.
Motion: Approve the Modification
Vote: For: 10, Against: 0, Abstained: 0, Recused: 0

Short Title: Therapeutic modulation of comorbid pain conditions

Investigator: Richard Traub
ID: IBC-00008261
Analyst: John O'Neill
VA-Related: No
Discussion: This modification involves the addition of two AAV constructs which will be used in animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-4-a and is approved using ABSL-1 facilities and practices.
Motion: Approve the Modification
Vote: For: 10, Against: 0, Abstained: 0, Recused: 0

7 RMSA Follow Up

Short Title: Adeno-associated viral (AAV) gene insertion to manipulate neural activity during natural and drug reward seeking behaviors
Investigator: Donna Calu
ID: IBC-00003239
Analyst: Holda Ramos
VA-Related: No
Discussion: This protocol has been modified to add new AAV constructs to be used in animals. This work is classified by the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules as III-D-4-a and is approved using BSL-1 and ABSL-1 facility and practices. The following modifications were made to secure approval: 1) Reconciled the genes of interest section with proteins expressed and 2) Updated the origin of the vectors.
Status: Approved

Short Title: Adeno-associated viral (AAV) gene insertion to manipulate neural activity during natural and drug reward seeking behaviors
Investigator: Lynda Coughlan
ID: IBC-00005922
Analyst: John O'Neill
VA-Related: No
Discussion: This modification involves the use of adenovirus DNA in a BAC used in *E. coli*. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-2-a using BSL-1 facilities and practices. This modification also involves the use of plasmids in mammalian cells. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-F-8 Appendix C-2 using BSL-2 facilities and practices. The following modifications were made to secure approval: 1) Limited the procedures in the locations section to the proposed work and 2) Described the PPE requirements referred to as "BSL-2+."
Status: Approved

Short Title: Cytoskeletal proteins in striated muscle pathophysiology
Investigator: Aikaterini Kontrogianni-Konstantopoulos
ID: IBC-00000466
Reviewer(s): Holda Ramos
VA Site: No
Discussion: This modification involved the addition of lentivirus in animals and cell culture. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-1-a and is approved using BSL-2/ABSL-2 facilities and practices with sharps precautions. It also involved a new gene of interest in previously approved work with plasmids in *E. coli* (III-F-8) and AAV in animals and cell culture (III-D-4-a) and is approved using BSL-1 and ABSL-1 facilities and practices. The following modifications were made to secure approval: 1) Confirmed the rooms where lentivirus will be used, 2) Clarified the origins of the genes of interest (organisms), 3) Clarified the pathogenicity statement, and 4) Added sharps precautions.
Status: Approved

8 Standard Operating Procedures and Plans

Short Title: Biological Agent Incident Response Plan (BAIRP)
Discussion: This plan was on the agenda for annual committee review. Changes made were minor, updating links, referenced documents, and contacts. Note that since this plan was added to the agenda, the Maryland Biological Agents Registry (BAR) Program has sent out notice that the main point of contact changed. The committee voted to approve the plan with this point of contact updated.
Motion: Approve
Vote: For: 10, Against: 0, Abstained: 0, Recused: 0

Short Title: HSFII-Specific SOP
Discussion: This plan was on the agenda for annual committee review. No significant changes were made.
Motion: Approve
Vote: For: 10, Against: 0, Abstained: 0, Recused: 0

Short Title: Barry-Specific SOP
Discussion: This plan was on the agenda for annual committee review. No significant changes were made.
Motion: Approve
Vote: For: 10, Against: 0, Abstained: 0, Recused: 0

Short Title: Ernst-Specific SOP
Discussion: This plan was on the agenda for annual committee review. No significant changes were made.
Motion: Approve

Vote: For: 9, Against: 0, Abstained: 0, Recused: 1 (Robert Ernst)

Short Title: Frieman-Specific SOP

Discussion: This plan was on the agenda for annual committee review. No significant changes were made.

Motion: Approve

Vote: For: 9, Against: 0, Abstained: 0, Recused: 1 (Matthew Frieman)

9 Non-Exempt Protocols with Periodic Reviews

Short Title: Identification of novel targets for the treatment of chemotherapy-induced painful peripheral neuropathy

Investigator: Ohannes Melemedjian

ID: IBC-00005540

Analyst: John O'Neill

VA-Related: Yes

Summary: There have been no substantive changes to this protocol submission.

Short Title: ProSAAS-mediated neuroprotective mechanisms in Alzheimer's and Parkinson's diseases

Investigator: Iris Lindberg

ID: IBC-00004821

Analyst: Holda Ramos

VA-Related: No

Summary: There have been no substantive changes to this protocol submission.

Short Title: IBC: 2053GCCC: AUTO1 in relapsed or refractory B-ALL

Investigator: Jean Yared

ID: IBC-00005752

Analyst: Holda Ramos

VA-Related: No

Summary: There have been no substantive changes to this protocol submission.

Short Title: Cancer Biology and Novel Agents in Lung Cancer

Investigator: John Schmitz

ID: IBC-00007728

Analyst: John O'Neill

VA-Related: No

Summary: There have been no substantive changes to this protocol submission.

Short Title: Molecular mechanisms and therapeutic development for heart failure

Investigator: Ruya Liu

ID: IBC-00006935

Analyst: Holda Ramos

VA-Related: No
Summary: There have been no substantive changes to this protocol submission.

Short Title: Addiction, CAM gene variation and small molecule effects
Investigator: George Uhl
ID: IBC-00006592
Analyst: John O'Neill
VA-Related: Yes
Summary: There have been no substantive changes to this protocol submission.

Short Title: Immunopathogenesis and novel approaches for treatment of experimental uveitis
Investigator: Kamal Moudgil
ID: IBC-00006014
Analyst: Holda Ramos
VA-Related: No
Summary: There have been no substantive changes to this protocol submission.

Short Title: Iron homeostasis of bacterial pathogens
Investigator: Amanda Oglesby
ID: IBC-00001885
Analyst: John O'Neill
VA-Related: No
Summary: There have been no substantive changes to this protocol submission.

Short Title: IBC: Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in Participants With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Investigator: Kirti Shetty
ID: IBC-00007935
Analyst: John O'Neill
VA-Related: No
Summary: There have been no substantive changes to this protocol submission.

Short Title: Role of TLR4 signaling in Innate and Adaptive Responses to pathogens
Investigator: Stefanie Vogel
ID: IBC-00001187
Analyst: John O'Neill
VA-Related: No
Summary: There have been no substantive changes to this protocol submission.

Short Title: Differential regulation of CD4 T cells migration across lymphatic endothelium
Investigator: Jonathan Bromberg
ID: IBC-00004068

Analyst: Holda Ramos
VA-Related: No
Summary: There have been no substantive changes to this protocol submission.

Short Title: Regulation of myosin phosphorylation in fibroblasts
Investigator: Megan Rizzo
ID: IBC-00003036
Analyst: John O'Neill
VA-Related: No
Summary: There have been no substantive changes to this protocol submission.

Short Title: Utilization of Luciferase Transfected Cell Lines In Murine Models
Investigator: Hem Shukla
ID: IBC-00004596
Analyst: John O'Neill
VA-Related: No
Summary: There have been no substantive changes to this protocol submission.

Short Title: Chemical genetic study of endoplasmic reticulum (ER)-associated degradation
Investigator: Shengyun Fang
ID: IBC-00003961
Analyst: John O'Neill
VA-Related: No
Summary: There have been no substantive changes to this protocol submission.

Short Title: In Vivo calcium Imaging to assess sex differences in the activity of MnPN sleep neurons
Investigator: Jessica Mong
ID: IBC-00004558
Analyst: John O'Neill
VA-Related: No
Summary: There have been no substantive changes to this protocol submission.

Short Title: M3R, MMP1 and colon cancer dissemination
Investigator: Jean-Pierre Raufman
ID: IBC-00002060
Analyst: John O'Neill
VA-Related: Yes
Summary: There have been no substantive changes to this protocol submission.

Short Title: IBC: 2214GCCC:Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacel, a CAR-T Therapy in Participants With Newly Diagnosed Multiple Myeloma
Investigator: Mehmet Kocoglu

ID: IBC-00006970
Analyst: John O'Neill
VA-Related: No
Summary: There have been no substantive changes to this protocol submission.

Short Title: Elucidation of the anti-tumor effect of magnetic pulse stimulation in a syngeneic mouse model of pancreatic cancer
Investigator: Hem Shukla
ID: IBC-00004692
Analyst: John O'Neill
VA-Related: No
Summary: There have been no substantive changes to this protocol submission.

Short Title: A High-Throughput Drug Screening Assay for Focal Cortical Dysplasia
Investigator: Alexander Ksendzovsky
ID: IBC-00007489
Analyst: John O'Neill
VA-Related: No
Summary: There have been no substantive changes to this protocol submission.

Short Title: IBC: 2128GCCC: EXPANDED ACCESS PROTOCOL (EAP) OF IDECABTAGENE VICLEUCEL NONCONFORMING FOR COMMERCIAL RELEASE (HP-00095365)
Investigator: Mehmet Kocoglu
ID: IBC-00006104
Analyst: John O'Neill
VA-Related: No
Summary: There have been no substantive changes to this protocol submission.

Short Title: IBC Submission: PrTK03
Investigator: Mohummad Siddiqui
ID: IBC-00004568
Analyst: John O'Neill
VA-Related: Yes
Summary: There have been no substantive changes to this protocol submission.

Short Title: Targeting IL-6/IL-11/STAT3 pathways in cancer
Investigator: Jiayuh Lin
ID: IBC-00003674
Analyst: Holda Ramos
VA-Related: No
Summary: There have been no substantive changes to this protocol submission.

Short Title: In vitro gene silencing using siRNA
Investigator: Thomas Clemens
ID: IBC-00006883
Analyst: John O'Neill
VA-Related: No
Summary: There have been no substantive changes to this protocol submission.

Short Title: Apoptotic Mechanism of Maternal diabetes-induced Neural tube defects
Investigator: Peixin Yang
ID: IBC-00001322
Analyst: John O'Neill
VA-Related: No
Summary: There have been no substantive changes to this protocol submission.

Short Title: Novel Mechanisms of Beta-lactam Resistance in Staph aureus
Investigator: Som Chatterjee
ID: IBC-00004995
Analyst: Holda Ramos
VA-Related: No
Summary: There have been no substantive changes to this protocol submission.

Short Title: Viral Transduction of Striated Muscle
Investigator: Robert Bloch
ID: IBC-00000936
Analyst: John O'Neill
VA-Related: No
Summary: This modification has been administratively approved for changes in personnel.

Short Title: Investigation of host immune response to Clostridioides difficile infection and development of immunotherapies
Investigator: Hanping Feng
ID: IBC-00001771
Analyst: Holda Ramos
VA-Related: No
Summary: This modification has been administratively approved for changes in personnel.

Short Title: IBC: Understanding the mechanism of neurosensory disorders
Investigator: Zubair Ahmed

ID: IBC-00003271
Analyst: Holda Ramos
VA-Related: No
Summary: This modification involves the addition of plasmids in human cell culture. This work is classified by the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules as III-F-8 Appendix C-1 and has been administratively approved using BSL-2 and facilities and practices.

Short Title: Molecular and Cellular Physiology of HERG K channels
Investigator: Matthew Trudeau
ID: IBC-00001397
Analyst: John O'Neill
VA-Related: No
Summary: This modification has been administratively approved for changes in personnel and updates to the AUP and biosafety cabinet certification dates.

Short Title: Development of an In Vitro Cell Culture Model System of the Vagina to Study Microbiome Interactions
Investigator: Jacques Ravel
ID: IBC-00000967
Analyst: John O'Neill
VA-Related: No
Summary: This modification has been administratively approved for changes in personnel.

Short Title: Targeting IKK/NF-kappaB in prostate cancer
Investigator: Hancal Dan
ID: IBC-00002533
Analyst: Holda Ramos
VA-Related: No
Summary: There have been no substantive changes to this protocol submission.

Short Title: Ethanol Remodeling of Striatal Microcircuits
Investigator: Brian Mathur
ID: IBC-00002399
Analyst: Holda Ramos
VA-Related: No
Summary: This modification has been administratively approved for changes in personnel.

Short Title: Engineering adenoviral vectors as vaccines for infectious disease
Investigator: Lynda Coughlan
ID: IBC-00005922
Analyst: John O'Neill

VA-Related:	No
Summary:	This modification has been administratively approved for changes to personnel.
Short Title:	Chemopotential by Low Dose Fractionated Radiation Therapy for disseminated intra-abdominal cancers
Investigator:	France Carrier
ID:	IBC-00004044
Analyst:	Holda Ramos
VA-Related:	Yes
Summary:	This modification has been administratively approved for changes in personnel.
Short Title:	Study of Glucokinase Function in Pancreatic Beta Cells
Investigator:	Megan Rizzo
ID:	IBC-00001431
Analyst:	Holda Ramos
VA-Related:	No
Summary:	There have been no substantive changes to this protocol submission.
Short Title:	Intracerebroventricular AAV treatment in TBI
Investigator:	Prajwal Ciryam
ID:	IBC-00008307
Analyst:	John O'Neill
VA-Related:	No
Summary:	This protocol is an exact copy and replacement for IBC-00007369, which became unusable due to a technical glitch. The process of making this protocol will be counted as a periodic review.
Short Title:	Immunopathogenesis and novel approaches for treatment of experimental multiple sclerosis, lupus and diabetes
Investigator:	Kamal Moudgil
ID:	IBC-00002366
Analyst:	Holda Ramos
VA-Related:	No
Summary:	This modification has been administratively approved for a change in personnel.
Short Title:	Co-Targeting IL-6 and CDK4/6 Pathways as a Novel Approach of Preventive Therapy for Triple-Negative Breast Cancer
Investigator:	Jiayuh Lin
ID:	IBC-00006504
Analyst:	John O'Neill
VA-Related:	Yes
Summary:	This modification has been administratively approved for changes in personnel.

Short Title: Computational Approach to In Vivo Genome Editing in the Brain
Investigator: Mirosław Janowski
ID: IBC-00005346
Analyst: John O'Neill
VA-Related: Yes
Summary: This modification has been administratively approved for changes in personnel.

Short Title: Chlamydia Pathogenesis
Investigator: Jacques Ravel
ID: IBC-00000978
Analyst: John O'Neill
VA-Related: No
Summary: This modification has been administratively approved for changes in personnel.

Short Title: Rational targeting of protein translation for cancer treatments
Investigator: France Carrier
ID: IBC-00002549
Analyst: Holda Ramos
VA-Related: No
Summary: This modification has been administratively approved for changes in personnel.

Short Title: Shigella Vaccine Development
Investigator: Eileen M. Barry
ID: IBC-00000269
Analyst: John O'Neill
VA-Related: No
Summary: This modification has been administratively approved for a change in personnel.

Short Title: IL-1(β) regulation of perinatal brain injury
Investigator: Irina Burd
ID: IBC-00007015
Analyst: Holda Ramos
VA-Related: No
Summary: This protocol has been administratively approved for work with influenza in animals using BSL-2 and ABSL-2 facility and practices.

Short Title: DNA library production and delivery for manipulation and labeling of neurons in the rodent brain
Investigator: Alexandros Pouloupoulos
ID: IBC-00004060
Analyst: Holda Ramos

VA-Related: No
Summary: This modification has been administratively approved for changes in personnel.

Short Title: Cytoskeletal Regulation of Lung Endothelial Cell Barrier Function
Investigator: Konstantin Birukov
ID: IBC-00004000
Analyst: Holda Ramos
VA-Related: No
Summary: This modification involves the use of plasmids in human cell culture. This work is classified by the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules as III-F-8 Appendix C1 and has been administratively approved using BSL-2 and ABSL-2 facility and practices.

Short Title: Understanding the development of human influenza-specific memory B cells following immunization
Investigator: Franklin Toapanta
ID: IBC-00002573
Analyst: Holda Ramos
VA-Related: No
Summary: There have been no substantive changes to this protocol submission.